Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia by Sajkov, Dimitar et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Pulmonary Hypertension in Chronic Lung Diseases and/
or Hypoxia
Dimitar Sajkov, Bliegh Mupunga,
Jeffrey J. Bowden and Nikolai Petrovsky
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55681
1. Introduction
Pulmonary hypertension is a common complication in lung disease. In the most recent revised
classification of pulmonary hypertension (PH), chronic lung diseases or conditions with
alveolar hypoxia are included in WHO Group III of PH-related diseases (Table 1) [1,2]. In this
classification the structure of this group was for the most part unchanged. The heading has
been recently modified to denote cause and effect on PH development. The primary modifi‐
cation was to add a new category of chronic lung disease of a mixed obstructive and restrictive
pattern, which includes chronic bronchiectasis, cystic fibrosis and a syndrome characterized
by the combination of pulmonary fibrosis (mainly of the lower zones of the lung) and emphy‐
sema (mainly of the upper zones of the lung), in which the prevalence of PH is almost 50%.
Alveolar hypoxia and thereby PH may occur in distinct conditions including: parenchymal
lung disease, chronic airway diseases, ventilatory control abnormalities, residence at high
altitude, progressive neuromuscular diseases and mixed obstructive and restrictive lung
diseases [1,3,4]. As both the primary respiratory condition and PH may be associated with
dyspnoea, the latter often goes unrecognised. Therefore, data on PH prevalence in each of these
conditions is limited [5].
Prevalence of COPD-related PH is influenced by COPD progression, its heterogeneity, co-
morbidities and methods of measurement. In a retrospective cohort study of over 4000 patients
with advanced COPD awaiting lung transplant, a 30.4% prevalence of PH has been reported
[6]. Elevated pulmonary artery pressure (PAP) is common in severe emphysema, although it
may be independent of hypoxia [7]. However, the gold standard of measuring PAP by right
heart catheterization to define PH has not been applied in the majority of prevalence studies.
© 2013 Sajkov et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In end-stage cystic fibrosis, PH prevalence, defined as mean PAP ≥25 mmHg, has been reported
as high as 63% [8].
1. PAH
1.1 Idiopathic PAH (IPAH)
1.2 Heritable
1.2.1 BMPR2
1.2.2 ALK-1, endoglin (with or without hereditary haemorrhagic telangiectasia)
1.2.3 Unknown
1.3 Drugs and toxins induced
1.4 Associated with (APAH)
1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic haemolytic anaemia
1.5 Persistent pulmonary hypertension of the newborn
1' Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis
2. Pulmonary hypertension due to left heart disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension
5. PH with unclear and/or multifactorial mechanisms
5.1 Haematological disorders: myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis,
vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: tumoural obstruction, fibrosing mediastinitis, chronic renal failure on dialysis
BMPR2: bone morphogenetic protein receptor, type 2; ALK-1: activin receptor-like kinase 1 gene; APAH: associated pulmonary arterial
hypertension; PAH: pulmonary arterial hypertension.
From : Simonneau G et al, JACC 2009 [1].
Table 1. Classification of Pulmonary Hypertension
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In high altitude residents, PH prevalence is between 8-18% [9,10]. A geographical variation in
altitude-related PH prevalence may suggest differences in genetic susceptibility to develop‐
ment of PH in people living above 2000 m [11,12]. Variations have been observed in PAP
changes among individuals living in the same regions, with some familial clustering and ethnic
differences, although no definite gene polymorphism affecting PAP has been isolated [13].
Until recently there was disagreement whether intermittent hypoxia, such as occurs in
obstructive sleep apnoea (OSA), without primary lung or cardiovascular disease can cause
sustained PH. Recent studies have resolved this controversy by demonstrating that OSA is
associated with PH, with co-prevalence rates varying between 20-40% [14-16]. However, no
large population-based studies of PH prevalence in OSA have been reported and management
of PH in patients with OSA has been mainly directed to managing the primary condition.
2. Pathophysiology
Alveolar hypoxia is a potent stimulus for pulmonary vasoconstriction. It operates at the
endothelial level and is one of the most important pathways leading to PH development in
chronic lung diseases. Alveolar hypoventilation precipitates acute pulmonary vasoconstric‐
tion in some regions of the lungs, and vasodilation in others, causing physiological shunt.
Hypoxia causes pulmonary vasoconstriction leading to an increase in pulmonary vascular
resistance. Two mechanisms are postulated to underpin this phenomenon. Vasoconstriction
is achieved either through activation of a vasoconstrictor pathway or inactivation of a vaso‐
dilator pathway, or alternatively via the effects of hypoxia on the vascular smooth muscle [17].
Studies in rats exposed to hypoxia suggest that hypoxia-exposed arterioles develop smooth
muscle in the walls of non-muscular pre-capillary blood vessels, which persists after removal
of the stimulus and contributes to ongoing PH [9].
Hypoxic insults can be sustained or intermittent. In sleep-disordered breathing, the presence
of intermittent hypoxia has been linked to the development of systemic hypertension with
changes in the vasculature similar to the changes in PH. It remains undetermined whether
sustained or intermittent hypoxia elicits these changes through similar mechanisms [18].
Studies in mice and rats exposed to intermittent hypoxia, mimicking sleep disordered
breathing, showed development of sustained PH and right ventricular hypertrophy [17].
Treatment with CPAP in sleep-disordered breathing results in the reversal of PH, supporting
a role for acute hypoxic pulmonary vasoconstriction and endothelial dysfunction in these
patients [17,19].
Studies in mouse models of emphysema have suggested alternative mechanisms to the
vascular changes associated with PH in COPD patients, as the mice developed pulmonary
vascular changes independent of hypoxia indicative of a much more complex mechanism than
hypoxia alone [5,20].
The development of PH as a result of hypoxic insults, both intermittent and chronic, is subject
to ongoing investigations, with several pathways implicated in hypoxic pulmonary vasocon‐
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striction (HPV). However, neither the oxygen sensing process nor the exact HPV pathways
are fully understood [21]. The effector pathway is suggested to include L-type calcium
channels, non-specific cation channels and voltage-dependent potassium channels, whereas
mitochondria and nicotinamide adenine dinucleotide phosphate oxidases have been described
as oxygen sensors (Figure 1). Reactive oxygen species (ROS), redox couples and adenosine
monophosphate-activated kinases are also under investigation as mediators of HPV. More‐
over, the role of calcium sensitisation, intracellular calcium stores and direction of change of
reactive oxygen species is still under debate. Other pathways, such as the endothelin-1
pathway, nitric oxide pathway and ROS may also explain development of sustained PH.
Endothelin-1 is an important mediator of systemic hypertension in intermittent hypoxic states
[18,22] and ongoing studies suggest a role for endothelin in acute HPV. ROS are highly reactive
and unstable free radicals. Intermittent hypoxia stimulates the synthesis and release of ROS
through the tyrosine hydroxylase system, leading to the development of systemic hyperten‐
sion. ROS have also been implicated in the induction of endothelin-1 and in angiotensinogen
synthesis with all these agents believed to contribute to the development of PH induced by
intermittent hypoxia [18,21,23].
Figure 1. Pathways involved in hypoxic pulmonary vasoconstriction. Acute hypoxia results in an increase of intracellu‐
lar calcium in pulmonary arterial smooth muscle cells and thus contraction. This increase in calcium is achieved by in‐
flow of extracellular calcium through plasmalemnal calcium channels and release of intracellularly stored calcium.
Hypoxic effects could be mediated or modulated by a decrease (left side) or increase (right side) of reactive oxygen
species (ROS). NADPH: reduced nicotinamide adenine dinucleotide phosphate; NSCC: nonspecific cation channels;
TRP: transient receptor potential; NADH: reduced nicotinamide adenine dinucleotide; NAD: nicotinamide adenine di‐
nulceotide; NADP: nicotinamide adenine dinucleotide phosphate; CCE: capacitative calcium entry; ATP: adenosine tri‐
phosphate; IP3: inositol triphosphate; cADPR: cyclic ADP-ribose; SR: sarcoplasmatic reticulum; Sommer N et al. Eur
Respir J 2008 [21], Reproduced with permission of the European Respiratory Society
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3. Pulmonary vascular remodelling
Studies of the vasculature in hypoxic PH have demonstrated changes including intimal
thickening, medial hypertrophy and muscularization of the small arterioles [5]. When the
balance between apoptosis and proliferation of endothelial cells in the pre-capillary pulmonary
blood vessels, in particular, is altered in favour of proliferation, the overall resistance pattern
is increased [24]. As shown in neonatal calves and rodent models, chronic hypoxia triggers
endothelial cell proliferation [24,25]. Acute hypoxia triggers adventitial fibroblast proliferation
within hours of exposure while medial hypertrophy and hyperplasia takes longer to develop
[24,26,27]. Fibroblasts stimulated by chronic hypoxia can transform into smooth muscle cells.
Hyperplasia is more prevalent in the less muscular arterioles, while hypertrophy is more
common in the muscular arterioles. Chronic hypoxia in rat models results in a doubling of
muscular arteries with proliferation into non-muscularized vessels [24]. The response of
pulmonary vascular smooth muscle cells to acute hypoxia is still debatable with some studies
indicating reduction in proliferation [24,28].
4. Role of systemic inflammation
Inflammation associated with underlying lung disease may be partly responsible for the
development of PH in hypoxic states. Inflammatory cells have been detected in local vascular
structures in COPD patients, in addition to the evidence of systemic inflammation with raised
inflammatory markers, such as CRP and TNF–α [29,30]. In rats exposed to hypoxia, alveolar
macrophages play a critical role in the inflammatory process, with inflammation occurring in
the presence of reduced alveolar PaO2 [31]. In alveolar macrophage-depleted conditions,
systemic inflammation was not observed [32].
5. COPD and PH
There is a growing body of evidence supporting different phenotypes among patients with
COPD. These COPD phenotypes may be useful in defining patients who may benefit from
particular therapies or interventions more than others. Potential phenotypes may be defined
by symptoms, physiology, radiology and exacerbation history, although the relevant clinical
outcomes have not been defined [33].
A PH phenotype in COPD is potentially defined by perceivable effects on functional perform‐
ance status and mortality [5]. PH is an independent prognostic factor in COPD [34-36]. The
current accepted definition of PH in COPD is a mean PAP ≥ 25mmHg with underlying hypoxia.
PH ideally should be measured by right heart catheterization, which may not be feasible in
many cases. As an alternative, Doppler echocardiographic measurements have been used in
a number of studies, although Doppler can be technically challenging due to body habitus and
poor acoustic windows, precluding detection of a significant left heart pathology, which may
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also contribute to elevated pulmonary pressures [37]. Scharf et al. in a study of patients with
severe COPD, reported over 60% of subjects had elevated pulmonary capillary wedge
pressures [7]. The impact of PH on mortality in COPD is independent of age, lung function
and blood gas derangements [5].
PH has been associated with exercise limitation in patients with COPD. In a study of 362 pre-
transplant patients with COPD, PH (mean PAP ≥25mmHg) was associated with shorter 6-
minute walking distance (6MWD) after adjustments for demographics and lung function [38].
In a large retrospective study of COPD patients studied with right heart catheterization, PAP
had an inverse relationship with 6MWD [6]. A much smaller study of 29 COPD patients
assessed with Doppler echocardiography could not detect statistically significant differences
in cardiopulmonary exercise test parameters and 6MWD in patients with or without PH.
However, the authors acknowledged that the small sample size and lack of invasive measures
could restrict the generalisation of the results [39].
In patients with parenchymal lung disease PH is generally modest (mean PAP 25-35 mmHg).
While PAP at rest varies from normal to moderately elevated, it increases significantly during
exercise, sleep and acute infective exacerbations. Hilde et al. in a study of 98 patients with
COPD undergoing right heart catheterization reported a 27% prevalence of PH. Hemodynamic
response to exercise, including mean PAP, was abnormal and similar between the PH and non-
PH COPD patients [40].
In some patients with COPD PAP elevations can be more substantial (mean PAP ≥35mmHg).
In patients with only moderate pulmonary mechanical impairment, this is considered "out-of-
proportion" PH. A subset of COPD patients has been identified where progressive PH has
prognostic implications. The term “PH out-of-proportion to COPD” has been applied to this
group of patients. An unusual pattern of cardiopulmonary abnormalities has been described
in the patients with more severe PH, including mild to moderate airway obstruction, severe
hypoxemia, hypocapnia, and a very low diffusing capacity for carbon monoxide. The charac‐
teristics of this subset include the presence of obstructive airways disease and presence of
fibrosis. A relative preservation of lung function and severe PH in COPD is believed to define
this “vascular phenotype” [5]. Thabut et al. in a cluster analysis identified a subgroup of COPD
patients with out-of-proportion PH associated with severe hypoxia [41]. Chaouat et al. also
identified a similar cluster [42]. The challenge remains, however, to have uniformly applied
definition of PH in COPD. As with PH out-of-proportion to left heart disease, large random‐
ized, controlled, studies of medications approved for PAH are not available for PH out-of-
proportion for parenchymal lung disease.
6. Treatment of PH in COPD
Although treatment of PH in COPD is conceptually appealing, there are no clear guidelines
and no medications currently registered for the treatment of PH secondary to COPD. The
primary focus of treatment, therefore, even in the vascular phenotype of COPD involves
standard therapy with smoking cessation, bronchodilators, inhaled steroids, long-term oxygen
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therapy (LTOT) and pulmonary rehabilitation [43]. Symptomatic (non-disease modifying)
therapy for COPD-related PH includes LTOT, peripherally-acting calcium channel blockers
and non-pharmacological interventions such as activity pacing and relaxation therapies.
6.1. Long-term home oxygen therapy
The only therapy that has demonstrated a survival advantage in people with COPD and co-
existent PH is LTOT. Indications for LTOT include patients with severe hypoxemia or those
with moderate hypoxemia and cor pulmonale [44-46], as it reduces pulmonary artery pressure
[44,47].
LTOT is, however, relatively cumbersome and intrusive, with variable patient adherence.
Patients with the most severe COPD have the least reduction in PH with LTOT [44,46]. Patients
will often be concerned about the imposition of being physically reliant on a machine [48].
LTOT is also expensive, and may be associated with a small number of very serious adverse
events across the community, such as CO2 retention or burns, particularly where patients
continue to smoke [49-51]. Actual adherence rates to LTOT are not precisely known and reports
vary between 45 - 70% [52,53].
6.2. Evidence from pulmonary arterial hypertension
PAH includes idiopathic disease and disease secondary to connective tissue disorders such as
scleroderma and systemic lupus erythematosus. Current evidence points to the benefits of
prostanoids, endothelin antagonists and phosphodiasterase-5 (PDE-5) inhibitors as disease
modifying in these people [2].
Given the evidence from PAH, it is plausible that in PH secondary to COPD pulmonary
vasodilatation may improve the subjective sensation of dyspnoea and extend exercise
endurance. Pulmonary vasodilator treatment (alone or as an adjunct to oxygen supplementa‐
tion) might be useful to reduce dyspnoea and improve quality of life (QOL) in people with
COPD and secondary pulmonary hypertension. Potentially, if these interventions were of
benefit, improved physical independence, symptomatic control of dyspnoea and potentially
even extended survival could be achieved.
6.3. Prostanoids
Epoprostenol sodium is indicated for patients with idiopathic, heritable or connective tissue
disease related PAH (Group 1) as a continuous infusion [54]. Iloprost is a prostacyclin analogue
that can be administered orally, intravenously or as an aerosolised formulation [55]. These
have been shown to improve exercise tolerance and haemodynamic parameters in patients
with PAH.
However, evidence for the use of prostacyclin analogues in COPD-related PH is very limited
and current practice does not favour routine use of these medications. The primary concern
in using pulmonary vasodilators is related to worsening gas exchange due to ventilation/
perfusion (V/Q) inequality [5].
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6.4. Endothelin receptor antagonists (ERA)
Bosentan, an oral endothelin-1 receptor antagonist is registered for use in patients with PAH
in World Health Organisation (WHO) functional classes (FC) II-IV. It has been shown to reduce
pulmonary vascular resistance and moderately improve exercise tolerance in people with
mildly symptomatic disease. Hepatotoxicity and teratogenicity are potential toxicities [56].
Ambrisentan has been approved for PAH in WHO FC II-IV and has been shown to delay
disease progression and improve exercise tolerance in patients with PAH with lower levels of
hepatotoxicity [57].
Trials with endothelin receptor antagonists in patients with COPD and PH have suffered from
poor study design and the general trend was worsening gas exchange without improvement
in functional capacity.
6.5. Phosphodiesterase-5 (PDE-5) inhibitors
Sildenafil is a selective inhibitor of PDE-5, an enzyme that is specific for both lung and penile
vasculature. Although originally developed for treatment of erectile dysfunction, sildenafil is
an effective pulmonary vasodilator [58-60]. PDE-5 is found throughout the muscularized
pulmonary vascular tree, including in newly muscularized distal pulmonary arteries exposed
to hypoxia.
Sildenafil may be preferred to other vasodilator agents, particularly in patients with severe
COPD, PH and poor RV function, because hemodynamic effects are likely to be selective on
the pulmonary circulation. PDE-5 inhibition with sildenafil attenuates the rise in PAP and
vascular remodelling when given before chronic exposure to hypoxia and when administered
as a treatment during ongoing hypoxia-induced PH [61].
Previous trials in patients with PAH (primary or associated with scleroderma) showed that
sildenafil-induced pulmonary vasodilatation is well tolerated, increased exercise capacity,
decreased Borg dyspnoea index and WHO functional class and improved haemodynamics
[62,63]. Therefore, it has been proposed to consider the use of this medication in selected
patients with COPD-related PH, although clinical trials in this group are limited.
A recent randomized trial in 20 patients with COPD-associated PH demonstrated that
sildenafil improved pulmonary haemodynamics both at rest and during exercise, with mild
to moderate worsening of gas exchange at rest due to worsening V/Q mismatch [64]. A longer
duration of 3 months treatment with sildenafil did not significantly alter hemodynamic or
functional capacity [65]. A more recent cross-over trial of sildenafil and placebo in COPD-
related PH showed significant worsening of gas exchange at rest and quality of life indices
with no beneficial effect on exercise capacity [66].
6.6. Calcium channel blockers
The administration of vasodilator drugs has been proposed as an alternative or adjunct to oxygen
supplementation in the treatment of PH in COPD for a number of years. However, there remains
considerable controversy regarding the likely benefits of non-selective vasodilators [67-69].
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Reports of worsening ventilation / perfusion (V/Q) inequality [70,71], a lack of long-term
effectiveness (or development of tolerance) [72,73] and the high incidence of side effects [73]
have raised doubts about the benefits of a non-selective vasodilator treatment in COPD.
Calcium channel blockers of the dihydropyridine group are the most extensively studied
vasodilators in both PAH and PH secondary to COPD [70-85]. However, the non-selective
vasodilator properties of these drugs give frequent systemic side effects (e.g. ankle oedema,
headache, facial flushing), preventing their wider use in the COPD population. Their use is
largely limited to patients who demonstrate acute vasoreactivity testing [73].
In an earlier study by our group, felodipine, a non-selective dihydropyridine calcium channel
blocker, significantly improved pulmonary haemodynamics in patients with COPD and PH
[83]. Pulmonary vasodilatation in these patients was sustained for 3 months of treatment,
without development of tolerance or deterioration in gas exchange, although a high incidence
of vasodilator side effects was observed. A subsequent study by our group showed that
amlodipine was as effective as felodipine in improving pulmonary haemodynamics in patients
with COPD, with fewer side effects than felodipine [84]. One small randomised placebo-
controlled trial in patients with COPD and PH reported significant improvement of the
dyspnoea score and preserved cardiac output with nifedipine for one year, although there was
no significant survival benefit [85]. This supports the hypothesis that pulmonary vasodilata‐
tion in patients with severe COPD and PH may improve their functional performance,
dyspnoea and QOL, particularly if systemic vasodilatation side effects can be avoided.
An important practice point is that alternative causes of PH in patients with COPD, such as
concomitant sleep disordered breathing or chronic thromboembolic disease should be actively
investigated, as there are important treatment alternatives in these patients.
7. Sleep disordered breathing and PH
True prevalence of PH in OSA is unknown and ranges from 17 - 52% [86]. In our study of 27
patients with OSA 11 (41%) had mildly elevated PA pressures, mean PAP = 26 mmHg, in the
absence of cardiac or pulmonary disease [14].
OSA patients maintain normal daytime oxygenation but experience episodic hypoxic events
during sleep. Acute rises in PAP with sleep-disordered breathing have an inverse relationship
with the degree of oxygen desaturation. Pulmonary artery pressure is influenced by an
obstructive sleep apnoea cycle associated with changes to intra-thoracic pressure with the
changes most marked in REM sleep [87]. Three main mechanisms have been proposed
including hypoxia, mechanical factors and reflex mechanisms [16]. However, there are
conflicting data to support these proposed mechanisms. It has been observed that changes in
PA pressure were inversely correlated with the degree of arterial hypoxia [88, 89] while in
another study supplemental oxygen did not affect pulmonary artery pressures [90].
Our understanding of the relationship between OSA and PH is evolving following recent
studies. Twenty patients with OSA were treated for 4 months with CPAP and a decrease in
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the mean PAP by 13.9 mmHg was observed for all patients although only five had PH [19].
This reduction of PAP and hypoxic pulmonary vascular reactivity in OSA following CPAP
treatment was associated with improved pulmonary endothelial function due to the elimina‐
tion of intermittent hypoxemia [19]. A randomised controlled cross-over trial using sham and
effective CPAP in 23 patients with OSA (AHI = 44 ± 29.3/h) and 10 normal controls concluded
that severe OSA was independently associated with PH [86]. The clinical impact of PH in sleep-
disordered breathing remains under investigation. PH in OSA patients may lead to dyspnoea
and reduction in 6MWD, suggesting functional impairment [91]. In a study of 296 OSA patients
(AHI ≥ 20/hr) using nasal CPAP, pulmonary haemodynamics were not independently
associated with mortality [42]. There are no consensus guidelines to recommend routine
screening for PH in OSA. Although current data suggest improvement in PH when OSA is
treated with CPAP therapy, the significance of this improvement in the clinical context remains
unclear, particularly with mild to moderate PH observed in most patients with OSA.
8. High altitude PH
High altitude PH (HAPH) prevalence is between 5 and 18% in those living at ≥3000 metres
and may be more common in children than adults [9,11,92]. As mentioned previously, the
roles of the endothelin-1 and prostaglandin I2 pathways in the pathophysiology in high
altitude  associated  PH have  not  been  clearly  defined  [9].  Alteration  in  trans-membrane
transport of K+ and Ca2+ has been implicated in the process. Recent work by Beall et al. has
suggested a role of free radical-mediated reduction in NO bioavailability [93, 94].
Migration to a lower altitude reverses HAPH. However, due to family, social and economic
reasons, migration is not an option for some patients. As an alternative, sildenafil for 3 months
has been shown to reduce PAP, improve 6MWD and cardiac index in patients with HAPH [95].
Reduction in mean PAP of up to -6.9 mmHg and improvement in walking distance of up to
45 m was observed and sildenafil was well tolerated [95].
The role of endothelin receptor antagonists in HAPH is yet to be determined. A small rando‐
mised cross-over study of 8 patients on bosentan did not improve pulmonary pressures or
functional capacity when initiated prior to ascent during high intensity exercise [96]. Aceta‐
zolamide was successful in reducing pulmonary pressures and improving cardiac output at 6
months of therapy in patients with excessive erythrocytosis and HAPH [97]. Other drugs under
evaluation include angiotensin inhibitors and results of the ongoing studies are pending.
9. PH in Cystic Fibrosis (CF)
PH prevalence in CF population remains uncertain with figures as high as 21-59%. A retro‐
spective study of 179 pre-transplant CF patients revealed that 38.5% had PH with a RHC mean
PAP of ≥ 25 mmHg [98]. In a recent series of 57 CF patients with advanced lung disease
considered for lung transplant, 36 (63.2%) had PH [99]. Patients with PH were significantly
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more hypoxaemic than those without PH. A small number of patients (4) had more marked
PH with mean PAP ≥40 mmHg [99].
PH develops as a consequence of alveolar hypoxemia and progressive destruction of the lung
parenchyma and pulmonary vascular bed. However, other mechanisms may also be involved.
An early study of the prevalence and impact of PH in adult patients with CF reported PH in
7 of 17 patients (41%) with stable but severe lung disease. PH correlated with declining FEV1,
diurnal and nocturnal oxygen saturation [4]. However, Doppler echocardiography, although
used routinely as an initial screening test to estimate PAP, may frequently be inaccurate and
some studies report poor correlation with right heart catheter measures [99]. The clinical
impact of PH in most CF patients’ management is unclear, although a trend towards worsening
mortality has been observed in some small studies.
No properly conducted studies of PH management in CF have been reported.
10. PH in non-CF Bronchiectasis
There are no systematic studies to determine true prevalence of PH in bronchiectasis, which
is defined as a progressive and permanent dilatation of predominantly medium and small
airways. Bronchiectasis is often accompanied with significant airway obstruction and airflow
limitation, and is associated with considerable morbidity but low mortality.
In a recent study of 94 patients with bronchiectasis, 31 patients (32.9%) had PH, defined as
systolic PAP of ≥40 mmHg on Doppler echocardiography [100]. Significant correlation was
observed between right ventricular dimensions and systolic PAP (r = 0.74) while RV dimen‐
sions were inversely related to PaO2 values (r = - 0.37) suggesting a role for hypoxemia in the
development of PH [100].
CT scan-derived measurements of the pulmonary artery have been shown to correlate
favourably with the mean PAP derived from right heart catheterization [101-104]. In a study
of 91 patients with bronchiectasis, increasing PH as characterised by CT measurements of PA
dimensions was found to be an important prognostic marker [104].
As with CF patients, there is lack of data in managing PH in this group of patients.
11. PH in interstitial lung diseases
Interstitial lung diseases (ILD) are characterized by restrictive lung physiology with progres‐
sive impairment of gas exchange resulting in alveolar hypoxemia and PH. Mortality in these
conditions is predicted by the degree of hypoxemia, spirometry and functional capacity as
defined by 6MWD and presence of PH [105-108].
The prevalence of PH in IPF is high and varies between 32 - 85%. PH is mostly of moderate
severity although in a few patients pulmonary pressures may approximate systemic levels
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[109-111]. In one study of 212 patients with ILD screened by echocardiography and/or right
heart catheter 29 (14%) had PH and 13 (6%) had severe PH defined as PAP ≥ 35mmHg [112].
To clinically diagnose PH in ILD is a challenge due to the overlap of symptoms of breathless‐
ness and functional impairment in both conditions.
The pathophysiology of PH due to chronic lung fibrosis is under active investigation (Figure
2). Mechanisms other than alveolar hypoxemia and loss of parenchymal tissue may lead to
development of PH in this condition [113-115]. The development of pulmonary fibrosis was
closely linked in experimental studies to elevated pulmonary artery pressures [116]. Vascular
remodelling in ILDs is heterogeneous with fibrotic areas being less vascularised and normal
tissue being hyper-vascularised with the creation of anastomoses between capillaries and
pulmonary veins [108]. An imbalance has been observed between pro-angiogenic and anti-
angiogeneic factors with reduction of vascular endothelial growth factor (VEGF) and up-
regulation of epithelium-derived growth factor (EDGF). In animal models, reduction in VEGF
has been linked to endothelial apoptosis and PH [108,117]. Vascular smooth muscle cell growth
factors are thought to be released from apoptotic endothelial cells which in turn lead to
muscularization of the vasculature which augments PH [116,117]. In addition, endothelial
dysfunction with reduced levels nitric oxide and prostacyclins and increased presence of
vasoconstrictive mediators, such as endothelin-1 and thromboxanes may contribute to the
development of PH [108,116,117].
Recent experimental work focused on the role of adenosine in development of PH in chronic
lung disease [118]. Adenosine through G protein linked pathways has been associated with
progression of fibrotic lung disease and PH through the adenosine receptor, A2bR [118,119].
Karmouty-Quintana et al. were able to demonstrate that inhibition of the A2bR, by inhibition
or genetic removal of the receptor, slowed the progression of the fibrotic process and associated
PH in rodents [120].
Vascular remodelling has been observed in other forms of interstitial lung diseases. In systemic
sclerosis an autoimmune disorder involving skin fibrosis, respiratory complications are the
commonest causes of death [121]. The prevalence of PH in systemic sclerosis is as high as 45%
[115]. Autoantibodies, including anti-fibrillin and anti-EC antibodies, have been implicated in
endothelial apoptosis and endothelial injury with the resultant inflammatory reaction.
Advanced systemic sclerosis is associated with reduced capillary density which could
contribute to PH [108,122,123].
In sarcoid, granulomatous involvement of the pulmonary arteries with occlusion and peri‐
vascular inflammation, invasion of pulmonary veins with inflammatory cells, and direct
compression of the arteries by lymph nodes are thought to contribute to the development of
PH. Endothelin-1 has an important role in PH in sarcoid with high levels reported in the
broncho-alveolar fluid of affected patients [124]. Currently there is no clear evidence to suggest
a role for angiogenesis or endothelial injury in sarcoid-related PH [107,125].
Few small studies have suggested a possible role of vasodilators in attenuating the progression
of PH in ILD [126,127]. The development of PH in ILD is associated with high mortality, hazard
ratio for death of 8.5 (95%CI: 4-17) [128]. However, most guidelines do not recommend use of
PAH-specific treatments in patients with ILD [2,129].
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12. Developmental abnormalities and PH
In the largest registry to date, 42 (12%) of 362 children (< 18 years) with confirmed PH (defined as
mean PAP of ≥25mmHg) had associated respiratory diseases or hypoxemia [130]. Bronchopul‐
monary dysplasia (BPD) was the commonest condition; other disorders included congenital
diaphragmatic  hernia,  congenital  pulmonary  hypoplasia  and  kyphoscoliosis  [130].  BPD
traditionally was defined by the presence of persistent respiratory distress, abnormal chest
radiography and requirement for oxygen supplementation [131]. With improvements in neonatal
care, persistent lung disease after prematurity is no longer characterised by florid fibro-prolifer‐
ative lung disease, but reduced vascular development and enlargement of distal airspaces
associated with impaired gas exchange and development of PH [132]. Congenital diaphragmat‐
ic hernia presents similarly and is associated with variable lung growth leading to persistent PH
[133]. Specific drug treatments for PH in this group of disorders have not been studied.
Figure 2. Concept for the development of pulmonary hypertension (PH) in IPF/UIP. Epithelial injury with subsequent
production of different mediators is the hallmark of fibrosis induction. These mediators induce fibroblast activation
with extracellular matrix (ECM) deposition, which leads to fibrosis. Some of these mediators (e.g., TGF-β) also activate
ECs and, as a result of a shift in favor of increased angiostatic (e.g., pigment epithelium–derived factor [PEDF]) and
reduced angiogenic factors (e.g., vascular endothelial growth factor [VEGF]), EC apoptosis results. Apoptotic ECs pro‐
duce less vasodilators, but more vasoconstrictors, which leads to augmented vasoconstriction of smooth muscle cells
(SMCs). At the same time, EC apoptosis gives rise to a reduction in vascular density, but also to enhanced production
of vascular SMC (VSMC) growth factors, which is important for remodeling of mesenchymal cells in the PA wall. How‐
ever, EC apoptosis also results in proliferation of apoptosis-resistant ECs or endothelial progenitors, with the conse‐
quence of angioproliferative lesions, including plexiform lesions. Another component of PA wall remodeling is the
release of additional factors generated in the fibrotic tissue, which contribute to PA wall remodeling from the outside
of the vessel; Farkas L et al., AJRCMB 2011 [107], Reprinted with permission of the American Thoracic Society.
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13. Conclusions
Pulmonary hypertension in chronic lung disease and/or hypoxia is  a  relatively common
complication caused by complex pathophysiologic processes. Alveolar hypoxia, either sus‐
tained or repetitively intermittent, triggers the development of PH, although other mecha‐
nisms are also important. Development of PH is associated with worsening dyspnoea with the
long-term prognosis dependant on the underlying disease process. Treatment of PH is largely
defined by the underlying lung pathology. Therefore, etiological diagnosis and assessment of
PH by WHO functional class is critical for management. Different classes of drug therapies have
been developed as a result of our current understanding of the pathophysiology of PH. Although
the treatments have had some impact on the progression of PH, further research is required to
more fully understand the condition and develop better therapeutic approaches.
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